Member's groups
Viewing 1 group
- active 1 week, 5 days ago
Rucaparib, a potent PARP inhibitor, has emerged as a vital medication in the treatment of advanced ovarian and prostate cancers, particularly in patients with specific genetic mutations. Its ability to target […]
Viewing 1 group